Phio Pharmaceuticals Corp.
PHIOReported to SECin USCIK 0001533040Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 12. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Plott Ronald Todd— | Open-market buy | $5,2005,000 shares | Sep 30, 2026 | Plott Ronald Todd | $5,200 | Open-market buy | 5,000 | Sep 30, 2026 |
| Plott Ronald Todd— | Open-market buy | $5,1505,000 shares | Sep 30, 2026 | Plott Ronald Todd | $5,150 | Open-market buy | 5,000 | Sep 30, 2026 |
| Bitterman Robert JChairman, Pres. & CEO | Award | nothing paid400,000 shares | Sep 29, 2026 | Bitterman Robert JChairman, Pres. & CEO | nothing paid | Award | 400,000 | Sep 29, 2026 |
| Plott Ronald Todd— | Award | nothing paid17,000 shares | Sep 29, 2026 | Plott Ronald Todd | nothing paid | Award | 17,000 | Sep 29, 2026 |
| Carson Lisa CabottChief Financial Officer | Award | nothing paid108,000 shares | Sep 29, 2026 | Carson Lisa CabottChief Financial Officer | nothing paid | Award | 108,000 | Sep 29, 2026 |